Immunotherapy has revolutionized the treatment of human cancers, with immune checkpoint inhibitors (ICIs) such as anti-PD-1/PD-L1 and anti-CTLA4 therapies being extensively utilized in clinical settings for various cancer patients. The gene discussed is PDCD1; the disease is cancer.